Cargando…
Chemokine CXCL13 in serum, CSF and blood–CSF barrier function: evidence of compartment restriction
BACKGROUND AND PURPOSE: Elevation of the chemokine CXCL13 in CSF frequently occurs during active and acute CNS inflammatory processes and presumably is associated with B cell-related immune activation. Elevation levels, however, vary a lot and “leaking” of CXCL13 from blood across dysfunctional brai...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7038591/ https://www.ncbi.nlm.nih.gov/pubmed/32089130 http://dx.doi.org/10.1186/s12987-020-0170-5 |
_version_ | 1783500674091188224 |
---|---|
author | Pilz, Georg Sakic, Irma Wipfler, Peter Kraus, Jörg Haschke-Becher, Elisabeth Hitzl, Wolfgang Trinka, Eugen Harrer, Andrea |
author_facet | Pilz, Georg Sakic, Irma Wipfler, Peter Kraus, Jörg Haschke-Becher, Elisabeth Hitzl, Wolfgang Trinka, Eugen Harrer, Andrea |
author_sort | Pilz, Georg |
collection | PubMed |
description | BACKGROUND AND PURPOSE: Elevation of the chemokine CXCL13 in CSF frequently occurs during active and acute CNS inflammatory processes and presumably is associated with B cell-related immune activation. Elevation levels, however, vary a lot and “leaking” of CXCL13 from blood across dysfunctional brain barriers is a possible source. The aim was to clarify the relation between CXCL13 concentrations in CSF, CXCL13 concentrations in serum and blood–CSF barrier (BCSFB) function for a correct interpretation of the intrathecal origin of CXCL13. METHODS: We retrospectively analyzed CXCL13 of banked CSF/serum samples (n = 69) selected from patient records and categorized the CSF CXCL13 elevations as CXCL13 negative (< 30 pg/ml), low (30–100 pg/ml), medium (101–250 pg/ml), or high (> 250 pg/ml). CXCL13 concentrations in CSF and serum and the corresponding CSF/serum CXCL13 quotients (Qcxcl13) were compared to CSF/serum albumin quotients (QAlb) as a measure for BCSFB function. The CXCL13 negative category included two subgroups with normal and dysfunctional BCSFB. RESULTS: Serum CXCL13 concentrations were similar across categories with median levels around 100 pg/ml but differed between individuals (29 to > 505 pg/ml). Despite clear evidence in serum, CXCL13 was detectable only at trace amounts (medians 3.5 and 7.5 pg/ml) in CSF of the two CXCL13 negative subgroups irrespective of a normal or pathological QAlb. Moreover, we found no association between CSF and serum CXCL13 levels or between QAlb and CSF CXCL13 levels in any of the CSF CXCL13-delineated categories. CXCL13 apparently does not “leak” from blood into CSF. This implies an intrathecal origin also for low CSF CXCL13 levels and a caveat for analyzing the Qcxcl13, because higher serum than CSF concentrations arithmetically depress the Qcxcl13 resulting in misleadingly low CSF/serum quotients. CONCLUSION: We demonstrated that CXCL13 does not cross from blood into CSF, not even during severe BCSFB dysfunction. CSF CXCL13 elevations therefore most likely always are CNS-derived, which highlights their relevance as indicator of inflammatory CNS processes. We recommend data should not be corrected for BCSFB permeability (QAlb) and not to calculate CSF/serum quotients for CXCL13 as these may introduce error. |
format | Online Article Text |
id | pubmed-7038591 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-70385912020-03-02 Chemokine CXCL13 in serum, CSF and blood–CSF barrier function: evidence of compartment restriction Pilz, Georg Sakic, Irma Wipfler, Peter Kraus, Jörg Haschke-Becher, Elisabeth Hitzl, Wolfgang Trinka, Eugen Harrer, Andrea Fluids Barriers CNS Research BACKGROUND AND PURPOSE: Elevation of the chemokine CXCL13 in CSF frequently occurs during active and acute CNS inflammatory processes and presumably is associated with B cell-related immune activation. Elevation levels, however, vary a lot and “leaking” of CXCL13 from blood across dysfunctional brain barriers is a possible source. The aim was to clarify the relation between CXCL13 concentrations in CSF, CXCL13 concentrations in serum and blood–CSF barrier (BCSFB) function for a correct interpretation of the intrathecal origin of CXCL13. METHODS: We retrospectively analyzed CXCL13 of banked CSF/serum samples (n = 69) selected from patient records and categorized the CSF CXCL13 elevations as CXCL13 negative (< 30 pg/ml), low (30–100 pg/ml), medium (101–250 pg/ml), or high (> 250 pg/ml). CXCL13 concentrations in CSF and serum and the corresponding CSF/serum CXCL13 quotients (Qcxcl13) were compared to CSF/serum albumin quotients (QAlb) as a measure for BCSFB function. The CXCL13 negative category included two subgroups with normal and dysfunctional BCSFB. RESULTS: Serum CXCL13 concentrations were similar across categories with median levels around 100 pg/ml but differed between individuals (29 to > 505 pg/ml). Despite clear evidence in serum, CXCL13 was detectable only at trace amounts (medians 3.5 and 7.5 pg/ml) in CSF of the two CXCL13 negative subgroups irrespective of a normal or pathological QAlb. Moreover, we found no association between CSF and serum CXCL13 levels or between QAlb and CSF CXCL13 levels in any of the CSF CXCL13-delineated categories. CXCL13 apparently does not “leak” from blood into CSF. This implies an intrathecal origin also for low CSF CXCL13 levels and a caveat for analyzing the Qcxcl13, because higher serum than CSF concentrations arithmetically depress the Qcxcl13 resulting in misleadingly low CSF/serum quotients. CONCLUSION: We demonstrated that CXCL13 does not cross from blood into CSF, not even during severe BCSFB dysfunction. CSF CXCL13 elevations therefore most likely always are CNS-derived, which highlights their relevance as indicator of inflammatory CNS processes. We recommend data should not be corrected for BCSFB permeability (QAlb) and not to calculate CSF/serum quotients for CXCL13 as these may introduce error. BioMed Central 2020-02-24 /pmc/articles/PMC7038591/ /pubmed/32089130 http://dx.doi.org/10.1186/s12987-020-0170-5 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Pilz, Georg Sakic, Irma Wipfler, Peter Kraus, Jörg Haschke-Becher, Elisabeth Hitzl, Wolfgang Trinka, Eugen Harrer, Andrea Chemokine CXCL13 in serum, CSF and blood–CSF barrier function: evidence of compartment restriction |
title | Chemokine CXCL13 in serum, CSF and blood–CSF barrier function: evidence of compartment restriction |
title_full | Chemokine CXCL13 in serum, CSF and blood–CSF barrier function: evidence of compartment restriction |
title_fullStr | Chemokine CXCL13 in serum, CSF and blood–CSF barrier function: evidence of compartment restriction |
title_full_unstemmed | Chemokine CXCL13 in serum, CSF and blood–CSF barrier function: evidence of compartment restriction |
title_short | Chemokine CXCL13 in serum, CSF and blood–CSF barrier function: evidence of compartment restriction |
title_sort | chemokine cxcl13 in serum, csf and blood–csf barrier function: evidence of compartment restriction |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7038591/ https://www.ncbi.nlm.nih.gov/pubmed/32089130 http://dx.doi.org/10.1186/s12987-020-0170-5 |
work_keys_str_mv | AT pilzgeorg chemokinecxcl13inserumcsfandbloodcsfbarrierfunctionevidenceofcompartmentrestriction AT sakicirma chemokinecxcl13inserumcsfandbloodcsfbarrierfunctionevidenceofcompartmentrestriction AT wipflerpeter chemokinecxcl13inserumcsfandbloodcsfbarrierfunctionevidenceofcompartmentrestriction AT krausjorg chemokinecxcl13inserumcsfandbloodcsfbarrierfunctionevidenceofcompartmentrestriction AT haschkebecherelisabeth chemokinecxcl13inserumcsfandbloodcsfbarrierfunctionevidenceofcompartmentrestriction AT hitzlwolfgang chemokinecxcl13inserumcsfandbloodcsfbarrierfunctionevidenceofcompartmentrestriction AT trinkaeugen chemokinecxcl13inserumcsfandbloodcsfbarrierfunctionevidenceofcompartmentrestriction AT harrerandrea chemokinecxcl13inserumcsfandbloodcsfbarrierfunctionevidenceofcompartmentrestriction |